Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application

RM Paragliola, A Corsello, V Del Gatto… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …
被引用次数：10 相关文章

Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application

RM Paragliola, A Corsello, V Del Gatto… - … OPINION ON DRUG …, 2020 - publicatt.unicatt.it
Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …

Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application

RM Paragliola, A Corsello… - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …

Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application.

RM Paragliola, A Corsello, V Del Gatto… - Expert Opinion on …, 2019 - europepmc.org
Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …